OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+29.73%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$64.3M
AUM Growth
+$64.3M
(+73%)
Cap. Flow
+$18.9M
Cap. Flow
% of AUM
29.39%
Top 10 Holdings %
Top 10 Hldgs %
51.17%
Holding
76
New
37
Increased
5
Reduced
25
Closed
2
Top Buys
| 1 |
Direxion Daily S&P Biotech Bull 3X Shares
LABU
|
$1.72M |
| 2 |
Bristol-Myers Squibb
BMY
|
$1.57M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
$1.2M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$1.11M |
| 5 |
uniQure
QURE
|
$848K |
Top Sells
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
$870K |
| 2 |
Biogen
BIIB
|
$320K |
| 3 |
Exelixis
EXEL
|
$243K |
| 4 |
Ionis Pharmaceuticals
IONS
|
$177K |
| 5 |
CELG
Celgene Corp
CELG
|
$139K |
Sector Composition
| 1 | Healthcare | 65.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GTHX
51
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $346K | 0.47% | +20,844 | New | +$346K |
|
|
AMRN
52
Amarin Corp
AMRN
$311M
| $345K | 0.47% | +16,641 | New | +$345K |
|
53
Xencor
XNCR
$580M
| $340K | 0.46% | +10,935 | New | +$340K |
|
54
Agios Pharmaceuticals
AGIO
$2.19B
| $324K | 0.44% | 4,806 -309 | -6% | -$20.8K |
|
55
Acadia Pharmaceuticals
ACAD
$4.38B
| $322K | 0.44% | 11,981 -2,918 | -20% | -$78.4K |
|
|
CKPT
56
DELISTED
Checkpoint Therapeutics
CKPT
| $322K | 0.44% | 112,760 | – | – |
|
57
Sangamo Therapeutics
SGMO
$157M
| $320K | 0.43% | +33,529 | New | +$320K |
|
58
Bio-Techne
TECH
$8.5B
| $308K | 0.42% | 1,551 -211 | -12% | -$41.9K |
|
59
Charles River Laboratories
CRL
$8.04B
| $307K | 0.42% | 2,112 -553 | -21% | -$80.4K |
|
60
IQVIA
IQV
$32.4B
| $286K | 0.39% | 1,985 -658 | -25% | -$94.8K |
|
61
Alkermes
ALKS
$4.78B
| $282K | 0.38% | 7,722 +117 | +2% | +$4.27K |
|
62
CytomX Therapeutics
CTMX
$336M
| $272K | 0.37% | +25,284 | New | +$272K |
|
|
63
Exelixis
EXEL
$10.1B
| $272K | 0.37% | 11,440 -10,206 | -47% | -$243K |
|
64
Grifois
GRFS
$6.78B
| $263K | 0.36% | 13,082 -4,094 | -24% | -$82.3K |
|
65
FibroGen
FGEN
$47.8M
| $262K | 0.36% | 4,827 -1,864 | -28% | -$101K |
|
66
United Therapeutics
UTHR
$13.8B
| $258K | 0.35% | 2,199 -465 | -17% | -$54.6K |
|
|
SURF
67
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $253K | 0.34% | +53,063 | New | +$253K |
|
68
Neurocrine Biosciences
NBIX
$13.8B
| $247K | 0.33% | 2,807 -179 | -6% | -$15.8K |
|
69
Gilead Sciences
GILD
$140B
| $238K | 0.32% | 3,667 -951 | -21% | -$61.7K |
|
70
Amgen
AMGN
$155B
| $236K | 0.32% | 1,242 -443 | -26% | -$84.2K |
|
71
Ligand Pharmaceuticals
LGND
$3.15B
| $219K | 0.3% | +1,745 | New | +$219K |
|
72
AC Immune
ACIU
$205M
| $201K | 0.27% | +39,801 | New | +$201K |
|
73
Precigen
PGEN
$1.34B
| $170K | 0.23% | 32,284 +5,175 | +19% | +$27.3K |
|
|
SCTL
74
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $67K | 0.09% | 11,353 | – | – |
|
|
75
Biogen
BIIB
$19.4B
| – | – | -1,062 | Closed | -$320K |
|